Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525403 | 0.92 | P2RX7 (0.32) | P2RX7DPP4DPP8DPP7CYP3A4 | |
| SCHEMBL7525111 | 0.85 | P2RX7 (0.36) | P2RX7DPP4DPP8DPP7DPP9 | |
| SCHEMBL7532232 | 0.85 | PDK1 (0.40) | P2RX7 | |
| SCHEMBL7527042 | 0.81 | KMT2A (0.39) | P2RX7 | |
| SCHEMBL7525099 | 0.81 | ESR1 (0.36) | P2RX7 | |
| SCHEMBL7528200 | 0.78 | P2RX7 (0.34) | P2RX7 | |
| SCHEMBL7528877 | 0.77 | PDK1 (0.39) | P2RX7 | |
| SCHEMBL7532744 | 0.74 | LMNA (0.37) | P2RX7 | |
| Trifluoroacetic Acid SCHEMBL7530146 | 0.71 | AOC3 (0.45) | P2RX7DPP4DPP8DPP7DPP9 | |
| SCHEMBL7529918 | 0.69 | PTGDR2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | BIOVITRUM AB (SE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002038153-A1 | NEW USE OF 4, 5, 6, 7-TETRAHYDROIMIDAZO-[4,5-C]PYRIDINE DERIVATIVES | BIOVITRUM AB (SE) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | AOC3, AOC2, AOC1 | P2RX7 2655/4885DPP4 2098/4885DPP8 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.